Compare AMBO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | VIVS |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.1M |
| IPO Year | 2010 | N/A |
| Metric | AMBO | VIVS |
|---|---|---|
| Price | $2.87 | $2.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.3K | ★ 35.2K |
| Earning Date | 08-05-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $9,699,000.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | $4.10 | ★ N/A |
| Revenue Growth | 23.73 | ★ 35.92 |
| 52 Week Low | $1.59 | $1.41 |
| 52 Week High | $6.75 | $21.96 |
| Indicator | AMBO | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 48.73 |
| Support Level | $2.70 | $1.96 |
| Resistance Level | $3.00 | $2.29 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 27.72 | 51.60 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.